Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors

Table 1

Table of HDACs inhibitors discussed in this paper, organized by class (refer to text for references).

HDACs inhibitor class	HDACs inhibitors	Other common identifiers	Clinical trial phase	Structure
Small molecular weight carboxylates	Valprioc acid	Depakene, Depakote, Depakote ER, Depakote Sprinkle	FDA-approved for epileps, seizures, mania, bipolar disorders, migranes Phase I/II in hematological malignancies and solid tumors
Hydroxamic Acids	Vorinostat	Suberoylanilide hydroxamic acid, (SAHA), Zolinza	FDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors
	Panobinostat	LBH589	Phase I/II in hematological malignancies and solid tumors
	Belinostat	PXD101	Phase I/II in hematological malignancies and solid tumors
Benzamides	Entinostat	MS-27-275, MS-275, SNDX-275	Phase I/II in hematological malignancies and solid tumors
	MGD0103	Mocetinostat	Phase I/II in hematological malignancies and solid tumors
Cyclic tetrapeptides	Romidepsin	Depsipeptide, Istodax, FK228, FR901228	FDA-approved for CTCL Phase I/II in hematological malignancies and solid tumors